RUA Life Sciences plc
RUA.L
London Stock Exchange21.00
GBp
+1.50
- -
RUA Life Sciences plc
RUA.L
(London Stock Exchange)
Recent
price
21.00
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- RUA Life Sciences plc is a medical device company specializing in the development, manufacturing, and commercialization of advanced implantable polyurethane technologies and related medical devices. The company offers core products and services including Elast-Eon, a leading long-term implantable polyurethane licensed globally; ECSil biomedical polymers used in spinal discs, cardiac pacing leads, and orthopedic applications; reaction injection molding (RIM) products for high-precision medical components; large bore vascular grafts; cardiovascular and soft tissue patches; and tri-leaflet polymeric heart valves. RUA Life Sciences also provides comprehensive contract development and manufacturing services to medical device and biotech companies, operating through four business segments: Biomaterials, Contract Manufacture, Vascular, and Structural Heart. The group serves markets in Europe, the United States, and internationally, with a focus on improving long-term implantable medical device performance using their proprietary polymer technology. Founded in 1996 and headquartered in Ayrshire, Scotland, the company was formerly known as AorTech International plc and reorganized under its current name in 2020. Recent major developments include the acquisition of Analytic Biosurgical Solutions SAS, expanding RUA's manufacturing capabilities in long-term implantable polymer devices. Over the past two years, the company has seen significant revenue growth with sales nearly doubling, supported by contributions across all business units, particularly in contract manufacturing and biomaterials. Strategic priorities focus on growing their heart valve and vascular graft products with ongoing regulatory and R&D progress. The company is also actively pursuing new business opportunities to further scale and diversify its product offerings. These efforts have brought the company close to break-even operationally while maintaining strong liquidity ratios. RUA Life Sciences continues to leverage its Elast-Eon polymer platform and expanding contract services as key drivers of growth and innovation in the implantable medical device industry. RUA Life Sciences operates as a holding company encompassing multiple specialized medical device businesses exploiting its proprietary polymer technology. Its integrated offerings span polymer licensing, device manufacturing, and tissue engineering products for cardiovascular and structural heart indications. The company maintains operations mainly across the UK, Europe, and the US, serving device manufacturers, healthcare providers, and biotech firms. Its continued strategic focus centers on advancing implantable polymeric medical devices with high biostability and long-term clinical performance, reinforcing its market position in the medical device industry. This comprehensive product and service portfolio combined with recent acquisitions and strong operational performance positions RUA Life Sciences as a growing player in the specialized medical device manufacturing and biomaterials sector. The company is listed on the London Stock Exchange under ticker RUA.